Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here:

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Default user image.

Olle Melander

Principal investigator

Default user image.

From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus


  • Kiran Musunuru
  • Alanna Strong
  • Maria Frank-Kamenetsky
  • Noemi E. Lee
  • Tim Ahfeldt
  • Katherine V. Sachs
  • Xiaoyu Li
  • Hui Li
  • Nicolas Kuperwasser
  • Vera M. Ruda
  • James P. Pirruccello
  • Brian Muchmore
  • Ludmila Prokunina-Olsson
  • Jennifer L. Hall
  • Eric E. Schadt
  • Carlos R. Morales
  • Sissel Lund-Katz
  • Michael C. Phillips
  • Jamie Wong
  • William Cantley
  • Timothy Racie
  • Kenechi G. Ejebe
  • Marju Orho-Melander
  • Olle Melander
  • Victor Koteliansky
  • Kevin Fitzgerald
  • Ronald M. Krauss
  • Chad A. Cowan
  • Sekar Kathiresan
  • Daniel J. Rader

Summary, in English

Recent genome-wide association studies (GWASs) have identified a locus on chromosome 1p13 strongly associated with both plasma low-density lipoprotein cholesterol (LDL-C) and myocardial infarction (MI) in humans. Here we show through a series of studies in human cohorts and human-derived hepatocytes that a common noncoding polymorphism at the 1p13 locus, rs12740374, creates a C/EBP (CCAAT/enhancer binding protein) transcription factor binding site and alters the hepatic expression of the SORT1 gene. With small interfering RNA (siRNA) knockdown and viral overexpression in mouse liver, we demonstrate that Sort1 alters plasma LDL-C and very low-density lipoprotein (VLDL) particle levels by modulating hepatic VLDL secretion. Thus, we provide functional evidence for a novel regulatory pathway for lipoprotein metabolism and suggest that modulation of this pathway may alter risk for MI in humans. We also demonstrate that common noncoding DNA variants identified by GWASs can directly contribute to clinical phenotypes.


  • Genomics, Diabetes and Endocrinology
  • Cardiovascular Research - Hypertension
  • EXODIAB: Excellence in Diabetes Research in Sweden
  • EpiHealth: Epidemiology for Health

Publishing year












Document type

Journal article


Nature Publishing Group


  • Cardiac and Cardiovascular Systems
  • Endocrinology and Diabetes



Research group

  • Genomics, Diabetes and Endocrinology
  • Cardiovascular Research - Hypertension


  • ISSN: 0028-0836